MARKET

FULC

FULC

Fulcrum
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.07
+0.46
+3.65%
Closed 16:11 03/01 EST
OPEN
13.02
PREV CLOSE
12.61
HIGH
13.82
LOW
12.81
VOLUME
93.71K
TURNOVER
--
52 WEEK HIGH
22.39
52 WEEK LOW
7.01
MARKET CAP
419.12M
P/E (TTM)
-4.5948
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, March 4, 2021 at 8:00 a.m. ET
CAMBRIDGE, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its fourth qua...
GlobeNewswire · 4d ago
Fulcrum Therapeutics Recognizes Rare Disease Day 2021
Theme of global unity highlights critical role of building communities of support for patients and families affected by rare diseases around the worldCAMBRIDGE, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-...
GlobeNewswire · 4d ago
Fulcrum Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire · 02/19 12:00
What Type Of Shareholders Own The Most Number of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares?
Simply Wall St. · 02/17 07:47
Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
GlobeNewswire · 01/22 21:00
Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced closing of its previously announced underwritten public offering of 4,6...
GlobeNewswire · 01/22 21:00
Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
CAMBRIDGE, Mass., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced closing of its prev...
GlobeNewswire · 01/22 21:00
Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
CAMBRIDGE, Mass., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced closing of its prev...
GlobeNewswire · 01/22 21:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FULC. Analyze the recent business situations of Fulcrum through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FULC stock price target is 18.17 with a high estimate of 23.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 86
Institutional Holdings: 21.53M
% Owned: 67.15%
Shares Outstanding: 32.07M
TypeInstitutionsShares
Increased
25
2.30M
New
17
148.57K
Decreased
12
867.68K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.13%
Pharmaceuticals & Medical Research
+1.38%
Key Executives
Chairman/Independent Director
Mark Levin
President/Chief Executive Officer/Director/Primary Contact
Robert Gould
Chief Operating Officer
Bryan Stuart
Senior Vice President
Diego Cadavid
Chief Scientific Officer
Christopher Moxham
Independent Director
James Collins
Independent Director
Katina Dorton
Independent Director
Alan Ezekowitz
Independent Director
James Geraghty
Independent Director
james Geraghty
Independent Director
Kate Haviland
  • Dividends
  • Splits
  • Insider Activity
No Data
About FULC
Fulcrum Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on improving the lives of patients with genetically defined rare diseases. The Company have developed a product engine which identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The Company is also engaged in developing drugs for the treatment for the root cause of muscle disorders, central nervous system disorders and blood disorders.

Webull offers kinds of Fulcrum Therapeutics Inc stock information, including NASDAQ:FULC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FULC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FULC stock methods without spending real money on the virtual paper trading platform.